Business ❯Pharmaceutical Industry

Market Trends

Drug Pricing Pricing Strategies Drug Development Stock Performance Novo Nordisk Weight Loss Drugs Drug Sales Sales Performance Investment Opportunities Consumer Behavior

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

It will be available only to early-stage patients with zero or one ApoE4 allele in a controlled access program pending European Commission approval.

U.S. Drug Launch Prices Skyrocket, Driven by Rare Disease Treatments

Counterfeit Ozempic Pens and Prescription Forgeries Raise Alarm in Germany

PAMI Updates Drug Subsidy Program with New Eligibility Rules and Full Coverage for Critical Treatments

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

UK Grants First Global Approval for GSK’s Blenrep in Two Combination Therapies

Pfizer Halts Development of Oral Weight-Loss Pill After Liver Injury

FDA Launches Roadmap to Phase Out Animal Testing in Drug Development

Eli Lilly's Mounjaro Launches in India, Targeting Obesity and Diabetes

Rising Use of Ozempic Raises Health, Ethical, and Social Concerns

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

Taxpayer-Funded Weight-Loss Drugs Face Scrutiny Over High Prices

Weight Loss Industry Transformed by New Drugs and Emerging Alternatives

Growing Demand for Weight-Loss Drugs in the UK Raises Safety and Accessibility Concerns

U.S. Obesity Rates Decline for First Time in Over a Decade

Amgen's Weight-Loss Drug Shows Promise but Faces Investor Skepticism

Reproductive Health Product Sales Surge Post-Trump Election Win

Limited Access to Popular Weight-Loss Drugs Highlights Socioeconomic Disparities

Supply and Cost Challenges Persist for Popular Weight-Loss Drugs

Cost and Efficacy Concerns Arise for GLP-1 Weight Loss Drugs